Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.

The American Red Cross urges donors to help the national blood supply recover from a severe shortage by offering free A1C testing, commonly used to screen for prediabetes and diabetes, in March. New ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon) receptor agonist.

Add Yahoo as a preferred source to see more of our stories on Google. Monitoring your A1C is essential for both preventing and managing type 2 diabetes. Why? Regular testing can help detect elevated ...

A new class of weight loss drug just took a major step toward approval for use. In a phase III clinical trial, medication ...

Lowering your A1C can significantly reduce your risk of heart disease. You can lower your A1C by eating more fiber and protein, cutting back on refined carbs, and more.